Overview
To explore the efficacy of a single low dose of esketamine for patients with irritable bowel syndrome (IBS).
Description
The investigators aim to investigate the efficacy of a single low dose of esketamine in patients with irritable bowel syndrome (IBS), and to explore the etiology of IBS and the effective and rapid treatment for this etiology.
Eligibility
Inclusion Criteria:
- Age of 18 - 60 years;
- American Society of Anesthesiologists (ASA) physical status of I - II;
- Body Mass Index (BMI) of 15 - 30;
- Scheduled for colonoscopy;
- Positive screening results according to the Rome IV diagnostic criteria for IBS;
- Patients who met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for Anxiety disorder (ANXD) and/or major depressive disorder (MDD) .
Exclusion Criteria:
- GastrointestinalTract (GI) bleeding;
- Any organic lesions confirmed by clinical examination, laboratory examination or colonoscopy；
- A previous diagnosis of colon cancer, infammatory bowel disease or coeliac disease;
- A history of weight loss (at least 10%) within six months;
- A history of abdominal surgery (other than hernia repair or appendectomy);
- Participate in other clinical trials within 3 months;
- Patients older than 55 years of age who have not undergone a colonoscopy in the past 5 years；
- Mental disorder patients with severe personality disorder, active suicidal ideation and history of self-harm within 1 year;
- Allergy or any contraindications to the drugs used in the study, such as severe cardiovascular disease, refractory hypertension, or hyperthyroidism;
- Drinking more than 50 units (1 unit refers to 10ml of pure alcohol) per week;
- Pregnancy or breastfeeding.